Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2015-03-30

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm501440qPMID 25734936PMCID PMC4955407
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Small-molecule inhibitors of the Myc oncoprotein.

  2015cited by this paper
• c-Myc Programs Fatty Acid Metabolism and Dictates Acetyl-CoA Abundance and Fate*

  2014cited by this paper
• Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis

  2014cited by this paper
• c-Myc programs fatty acid metabolism and dictates acetyl-CoA abundance and fate.

  2014cited by this paper
• The bromodomain: from epigenome reader to druggable target.

  2014cited by this paper
• Discovery of Methyl 4′‐Methyl‐5‐(7‐nitrobenzo[c][1,2,5]oxadiazol‐4‐yl)‐[1,1′‐biphenyl]‐3‐carboxylate, an Improved Small‐Molecule Inhibitor of c‐Myc–Max Dimerization

  2014cited by this paper
• Amphipathic α-helix mimetics based on a 1,2-diphenylacetylene scaffold.

  2013cited by this paper
• The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein–protein interactions with Bak

  2013cited by this paper
• Solid-Phase Methodology for Synthesis of O-Alkylated Aromatic Oligoamide Inhibitors of α-Helix-Mediated Protein–Protein Interactions

  2013cited by this paper
• Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.

  2013cited by this paper
• Recapitulating the α-helix: nonpeptidic, low-molecular-weight ligands for the modulation of helix-mediated protein-protein interactions.

  2013cited by this paper
• Pharmacophore identification of c-Myc inhibitor 10074-G5.

  2013cited by this paper
• MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells

  2013cited by this paper
• Disruption of Myc-Max Heterodimerization with Improved Cell-Penetrating Analogs of the Small Molecule 10074-G5

  2013cited by this paper
• Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.

  2012cited by this paper
• Place your BETs: the therapeutic potential of bromodomains.

  2012cited by this paper
• Addiction to c-MYC in multiple myeloma.

  2012cited by this paper
• Small-molecule inhibitors of dimeric transcription factors: Antagonism of protein–protein and protein–DNA interactions

  2012cited by this paper
• Mitochondrial Structure, Function and Dynamics Are Temporally Controlled by c-Myc

  2012cited by this paper
• Relaxation of the rigid backbone of an oligoamide-foldamer-based α-helix mimetic: identification of potent Bcl-xL inhibitors.

  2012cited by this paper
• Addicted to Myc--but why?

  2011cited by this paper
• BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

  2011cited by this paper
• Bromodomains as therapeutic targets

  2011cited by this paper
• Therapeutic targeting of Myc-reprogrammed cancer cell metabolism.

  2011cited by this paper
• c-Myc regulates transcriptional pause release.

  2010cited by this paper
• Selective inhibition of BET bromodomains

  2010cited by this paper
• In Vitro Cytotoxicity and In Vivo Efficacy, Pharmacokinetics, and Metabolism of 10074-G5, a Novel Small-Molecule Inhibitor of c-Myc/Max Dimerization

  2010cited by this paper
• Point Mutations in c-Myc Uncouple Neoplastic Transformation from Multiple Other Phenotypes in Rat Fibroblasts

  2010cited by this paper
• Myc roles in hematopoiesis and leukemia.

  2010cited by this paper
• The ups and downs of Myc biology.

  2010cited by this paper
• Therapeutic Targeting of Myc.

  2010cited by this paper
• Synthetic alpha-helix mimetics as agonists and antagonists of islet amyloid polypeptide aggregation.

  2010cited by this paper
• Oligobenzamide proteomimetic inhibitors of the p53–hDM2 protein–protein interaction

  2009cited by this paper
• Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation.

  2009cited by this paper
• Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc.

  2009cited by this paper
• c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle

  2008cited by this paper
• Reflecting on 25 years with MYC

  2008cited by this paper
• Modelling Myc inhibition as a cancer therapy

  2008cited by this paper
• Synthesis of functionalised aromatic oligamide rods.

  2008cited by this paper
• Improved low molecular weight Myc-Max inhibitors

  2007cited by this paper
• Selective Inhibition of c‐Myc/Max Dimerization by a Pyrazolo[1,5‐a]pyrimidine

  2007cited by this paper
• Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules.

  2006cited by this paper
• A credit-card library approach for disrupting protein-protein interactions.

  2006cited by this paper
• Conditional transgenic models define how MYC initiates and maintains tumorigenesis.

  2006cited by this paper
• Overexpression of c‐myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway

  2006cited by this paper
• Transcriptional regulation and transformation by Myc proteins

  2005cited by this paper
• Myc Stimulates Nuclearly Encoded Mitochondrial Genes and Mitochondrial Biogenesis

  2005cited by this paper
• Omomyc expression in skin prevents Myc-induced papillomatosis

  2004cited by this paper
• Low molecular weight inhibitors of Myc–Max interaction and function

  2003cited by this paper
• X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors.

  2003cited by this paper
• The many faces of c-MYC.

  2003cited by this paper
• c-MYC: more than just a matter of life and death

  2002cited by this paper
• Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts

  2002cited by this paper
• Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion.

  2002cited by this paper
• c-Myc regulates mammalian body size by controlling cell number but not cell size

  2001cited by this paper
• Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix.

  2001cited by this paper
• Translocations involving c-myc and c-myc function

  2001cited by this paper
• Analysis of c-myc DNA amplification in non-small cell lung carcinoma in comparison with small cell lung carcinoma using polymerase chain reaction

  2001cited by this paper
• Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc.

  2001cited by this paper
• Deconstructing myc.

  2001cited by this paper
• Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion.

  2000influential reference
• c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism

  1999cited by this paper
• MYC oncogenes and human neoplastic disease

  1999cited by this paper
• Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination.

  1997cited by this paper
• Distinct Roles for MAX Protein Isoforms in Proliferation and Apoptosis*

  1997cited by this paper
• NMRPipe: A multidimensional spectral processing system based on UNIX pipes

  1995cited by this paper
• Protein-ligand interactions: exchange processes and determination of ligand conformation and protein-ligand contacts.

  1994cited by this paper
• Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides.

  1994cited by this paper
• Oncogenic activity of the c-Myc protein requires dimerization with Max.

  1993cited by this paper
• Differential patterns of DNA binding by myc and max proteins.

  1993cited by this paper
• Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain

  1993cited by this paper
• c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.

  1992cited by this paper
• Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.

  1991cited by this paper
• Deregulated expression of c-myc by murine erythroleukaemia cells prevents differentiation

  1986cited by this paper
• Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene

  1985cited by this paper
• Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells.

  1982cited by this paper

• A novel aurora kinase molecular glue-based degrader sp-2-067 inhibits prostate cancer cell growth and alters immune profile.

  2026cites this paper
• Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS

  2026cites this paper
• Topologically Tunable α-Helix Mimetics for Targeting Protein-Protein Interactions.

  2025cites this paper
• Heterobifunctional proteomimetic polymers for targeted protein degradation

  2025cites this paper
• Razing the scaffolding: the elimination of non-catalytic functions of kinases through targeted protein degradation.

  2025cites this paper
• Oligo-benzamide-based peptide mimicking tools for modulating biology.

  2024cites this paper
• Tackling Undruggable Targets with Designer Peptidomimetics and Synthetic Biologics.

  2024cites this paper
• New insights into protein–protein interaction modulators in drug discovery and therapeutic advance

  2024cites this paper
• MYC the oncogene from hell: Novel opportunities for cancer therapy.

  2024cites this paper
• Recent advances in anti-tumor therapeutic approaches for the universally active transcriptional factor c-MYC

  2024cites this paper
• Design, synthesis, and activity evaluation of 2-iminobenzimidazoles as c-Myc inhibitors for treating multiple myeloma

  2024cites this paper
• Targeting Transcription Factors in Cancer: From "Undruggable" to "Druggable".

  2023cites this paper
• Aromatic oligoesters as novel helix mimetic scaffolds

  2023cites this paper
• Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma

  2023cites this paper
• MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products

  2023cites this paper
• Potential Therapeutics Targeting Upstream Regulators and Interactors of EHMT1/2

  2022influential citation
• MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner

  2022cites this paper
• A Modular Synthesis of Teraryl‐Based α‐Helix Mimetics, Part 5: A Complete Set of Pyridine Boronic Acid Pinacol Esters Featuring Side Chains of Proteinogenic Amino Acids

  2022cites this paper
• A Selective Small‐Molecule c‐Myc Degrader Potently Regresses Lethal c‐Myc Overexpressing Tumors

  2022cites this paper
• Normal and Neoplastic Growth Suppression by the Extended Myc Network

  2022cites this paper
• Ru(III) complexes with pyrazolopyrimidines as anticancer agents: bioactivities and the underlying mechanisms.

  2022cites this paper
• Cryptotanshinone inhibits ovarian tumor growth and metastasis by degrading c-Myc and attenuating the FAK signaling pathway

  2022cites this paper
• Synthesis and biological evaluation of a novel c-Myc inhibitor against colorectal cancer via blocking c-Myc/Max heterodimerization and disturbing its DNA binding.

  2022cites this paper
• The crystal structure of N-cyclohexyl-3-hydroxy-4-methoxybenzamide, C14H19NO3

  2022cites this paper
• Characterization of Hydrophilic α-Helical Hot Spots on the Protein-Protein Interaction Interfaces for the Design of α-Helix Mimetics

  2022cites this paper
• Drugging the 'undruggable'. therapeutic targeting of protein-DNA interactions with the use of computer-aided drug discovery methods.

  2021cites this paper
• A novel inhibitor L755507 efficiently blocks c-Myc–MAX heterodimerization and induces apoptosis in cancer cells

  2021cites this paper
• MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

  2021cites this paper
• Targeting MYCN in Pediatric and Adult Cancers

  2021cites this paper
• Developing Inhibitors to the Amino-Terminus Domains of Steroid Hormone Receptors

  2021cites this paper
• Synthesis and structure-activity relationship study of new biaryl amide derivatives and their inhibitory effects against hepatitis C virus

  2021cites this paper
• Synthesis and Evaluation of Arylamides with Hydrophobic Side Chains for Insulin Aggregation Inhibition.

  2021cites this paper
• Presence and structure‐activity relationship of intrinsically disordered regions across mucins

  2020cites this paper
• Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc

  2020cites this paper
• Evolution in non-peptide α-helix mimetics on the road to effective protein-protein interaction modulators.

  2020cites this paper
• Turning Up the Heat on MYC: Progress in Small-Molecule Inhibitors

  2020cites this paper
• Syntheses and Evaluation of New Bisacridine Derivatives for Dual Binding of G-Quadruplex and i-Motif in Regulating Oncogene c-myc Expression.

  2020cites this paper
• Lytic Induction Therapy against Epstein–Barr Virus-Associated Malignancies: Past, Present, and Future

  2020cites this paper
• Discovery of 4-(3,5-dimethoxy-4-(((4-methoxyphenethyl)amino)methyl)phenoxy)-N-phenylaniline as a novel c-myc inhibitor against colorectal cancer in vitro and in vivo.

  2020cites this paper
• Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein

  2020cites this paper
• Stapled Peptides as HIF‐1α/p300 Inhibitors: Helicity Enhancement in the Bound State Increases Inhibitory Potency

  2020cites this paper
• NSD3S stabilizes MYC through hindering its interaction with FBXW7

  2019cites this paper
• Targeting intrinsically disordered proteins at the edge of chaos.

  2019cites this paper
• Rhodamine-modified fluorescent half-sandwich iridium and ruthenium complexes: potential application as bioimaging and anticancer agents.

  2019cites this paper
• Suppression of c‐Myc using 10058‐F4 exerts caspase‐3‐dependent apoptosis and intensifies the antileukemic effect of vincristine in pre‐B acute lymphoblastic leukemia cells

  2019cites this paper
• Emerging strategies to target the dysfunctional cohesin complex in cancer

  2019cites this paper
• MYC modulators in cancer: a patent review

  2019cites this paper
• Identification and characterization of small molecules targeting MYC function

  2019cites this paper
• Crystal Structures and Nuclear Magnetic Resonance Studies of the Apo Form of the c-MYC:MAX bHLHZip Complex Reveal a Helical Basic Region in the Absence of DNA

  2019cites this paper
• Perspectives on drug discovery strategies based on IDPs

  2019cites this paper
• Potential anticancer agent for selective damage to mitochondria or lysosomes: Naphthalimide-modified fluorescent biomarker half-sandwich iridium (III) and ruthenium (II) complexes.

  2019cites this paper
• Theranostic Lysosomal Targeting Anticancer and Antimetastatic Agents: Half-Sandwich Iridium(III) Rhodamine Complexes

  2019cites this paper
• A Non-genetic Mechanism for Chemoresistance in Lung Cancer: The Role of Integrin β4/Paxillin Axis

  2019cites this paper
• Bridged α-helix mimetic small molecules.

  2019cites this paper
• Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.

  2019cites this paper
• A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation

  2018cites this paper
• Amphipathic helical peptides hamper protein-protein interactions of the intrinsically disordered chromatin nuclear protein 1 (NUPR1).

  2018influential citation
• Lysosome targeted drugs: rhodamine B modified N^N-chelating ligands for half-sandwich iridium(III) anticancer complexes

  2018cites this paper
• Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches

  2018cites this paper
• Endorsing cellular competitiveness in aberrant epithelium of oral submucous fibrosis progression: neighbourhood analysis of immunohistochemical attributes

  2018cites this paper
• Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm.

  2018cites this paper
• Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.

  2017cites this paper
• Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma

  2017influential citation
• Therapeutic Interventions of Cancers Using Intrinsically Disordered Proteins as Drug Targets: c-Myc as Model System

  2017cites this paper
• Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth

  2017cites this paper
• Ribosomopathy-like properties of murine and human cancers

  2017cites this paper
• Strategies to Inhibit Myc and Their Clinical Applicability

  2017cites this paper
• OncoPPi-informed discovery of Mitogen-Activated Protein Kinase Kinase 3 as a novel binding partner of c-Myc

  2017cites this paper
• Design, Synthesis, and Evaluation of New Selective NM23-H2 Binders as c-MYC Transcription Inhibitors via Disruption of the NM23-H2/G-Quadruplex Interaction.

  2017cites this paper
• The Quest for Targets Executing MYC-Dependent Cell Transformation

  2016cites this paper
• A Promising but Challenging Strategy for Cancer Treatment: Disruption of Myc-Max Heterodimerization

  2016cites this paper
• MOLECULAR RECOGNITION ENCODED WITHIN THE PRIMARY SEQUENCE OF DISORDERED PROTEINS

  2016cites this paper
• Concepts to Target MYC in Pancreatic Cancer

  2016cites this paper
• Targeting intrinsically disordered proteins in rational drug discovery

  2016cites this paper
• Synthesis of highly functionalized oligobenzamide proteomimetic foldamers by late stage introduction of sensitive groups† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c6ob00078a Click here for additional data file.

  2016cites this paper
• Probing Protein Surfaces: QSAR Analysis with Helix Mimetics

  2016cites this paper
• Targeting MYC in cancer therapy: RNA processing offers new opportunities

  2016cites this paper
• VOLIN and KJON—Two novel hyperdiploid myeloma cell lines

  2016cites this paper
• Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids

  2015cites this paper
• A quantitative, surface plasmon resonance-based approach to evaluating DNA binding by the c-Myc oncoprotein and its disruption by small molecule inhibitors.

  2015cites this paper
• State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors.

  2015cites this paper
• BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536.

  2015cites this paper
• Helix mimetics: Recent developments.

  2015cites this paper
• MYC as therapeutic target in leukemia and lymphoma

  2015cites this paper
• Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletion

  2015cites this paper